After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, which is enough for securing a partner ahead of the US launch in 2026 and completing the submission of Orviglance by the first half of August. If Ascelia can secure a strong US partner on good terms, our Base Case target price could be reached within three to twelve months.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/